Interview: Paweł Mazur – East Area Director, Accord Healthcare, Poland
As east area director for the vast CEE market, Pawel Mazur explains how Accord Healthcare has gone from strength to strength in Poland, with the intention of becoming a top…
Address: ul. Kubickiego 11, 02-954 Warszawa ,Poland
Tel: 22 642 07 75
Web: http://www.ranbaxy.com.pl/
The company Ranbaxy began to actively work on the Polish market in 1997. The first products introduced into the pharmaceutical market and achieved huge success. These were the drugs of the fluoroquinolone group: Cifran (Ciprofloxacyna) Zanocin (Oflaxacin) and Norbactin (Norfloxacyna). Based on the success which has had the launch of these drugs, introduced another new product which was Vercef (Cefaclor) – the first on the Polish market, the original generic formulation.
In the following years were registered and placed on the market with more modern antibiotics: Ramoclav (Co-Amoxycilinum) Rantaksym (Cefotaximum) Oframax (Ceftriaxonum). Antibiotics are historically the most important gupę drugs in the portfolio company, which is constantly developed and enriched with new medications, such as: Ceroxim (Cefuroxim axetil); Klabax (claritromycyna) and other
In the first half of 2003 the company started operations in the segment by introducing cardiac preparation Celipres (celiprolol) – betabloker third generation, and in the second half of the product Ramicor (Ramipril) – ACE Inhibitor modern. Both products have met with a very well received by doctors and patients, as confirmed by strong sales of these drugs, which in 2004 amounted to over PLN 2.5 million, in the following year, 2005 – PLN 3.3 million in 2006 – 8.2 million PLN . The portfolio of cardiovascular drugs is still under development and in early 2007, was enriched with the preparation Ranopril (lisinopril) – a drug used among others in leczniu hypertension.
At the end of 2006 the company introduced the sale, preparation called Melobax (Meloxicam) – a modern non-steroidal anti-inflammatory drug. Currently, the drug is used by about 10 000 patients per month.
In mid 2007 the company began selling Ranbaxy formulation Citabax (citalopram) – an antidepressant, an extremely safe activity profile. This product was very well received by doctors and patients. in subsequent years it is planned to introduce further psychiatric drugs.
The beginning of 2008 it also had extensive promotional activities in the segment of gastrointestinal drugs, related to the sale of modern proton pump inhibitor – lansoprazole (trade name Lanbax). This product will be a beginning of the line gastroenterological drugs promoted by the company.
According to IMS data Ranbaxy is 58 among all pharmaceutical companies in Poland. The company is the clear leader of sales growth, which takes place through the introduction of new products and increased sales of existing ones. Systematic increase in sales of Ranbaxy drugs confirms the high quality and high demand among physicians and patients.
The company now operates Ranbaxy 127 people, including 110 persons of field team responsible for maintaining contacts with the medical, aptekarskim and wholesale. Since 2006, the field team is divided into two groups Promo: Rambo 1 (40 representatives) and Rambo 2 (40 representatives). Created in 2008, the third group of promotion – Rambo 3 (20 representatives). All representatives of companies undergoing a very intense and professional training in product knowledge and medical issues with them związnych.
CEPODEM Cefpodoximum Antyinfekcyjny
DOXICIN Doxycyclinum Antyinfekcyjny
NEOPROST Bicalutamid Onkologia
NOBREC Anastrazol Onkologia
VENLABAX Venlafaxyna Psychiatria – leczenie depresji
XETIRAN Fluoxetinum CNS
As east area director for the vast CEE market, Pawel Mazur explains how Accord Healthcare has gone from strength to strength in Poland, with the intention of becoming a top…
Krzysztof Popławski, general manager of Baxter Poland, discusses the Baxter Education Center, the largest educational program for a European affiliate, and its role in raising the awareness within the Polish…
Hubert Niemyjski, country manager of Coloplast Poland and the Baltics, highlights the large differences between the market landscape of the company’s three pillars; ostomy, wound and continence care. Additionally, he…
Olympus is internationally well-regarded as being a quality camera provider and continues to provide developed countries across the globe with high-tech medical devices from endoscopes to imagery solutions. Tomasz Mrzygłód,…
Paweł Migdalski, CEO at Siemens Healthineers Poland, discusses the innovations they are bringing to the market and how they are building on the success of the Siemens Healthineers Academy. Furthermore,…
Tomasz Dzitko, founder and CEO of Delfarma, Poland’s leading parallel importer, gives an overview of the sector in Poland and its impact on the healthcare ecosystem, as well as the…
Piotr Steczniewski, president of Profarm PS – a successful wholesale family business – since 2012, shares how the company has managed to thrive over the years through constant adaptation to…
Łukasz Korybalski, regional manager of Becton Dickinson (BD) Central Eastern Europe, discusses the rising significance of the region as the company continues to grow and the strategic importance of Poland,…
Marzena Kulis, managing director of Johnson & Johnson Medical Devices CEE, highlights the importance of the region and Poland within J&J Medical Devices, and the impact of increasing healthcare expenditures…
Despite the global R&D excitement around oncology, cardiovascular death still remains the world’s largest killer, and according to OECD data, accounts for roughly a third of all mortalities. This trend…
Cezary Kilczewski, president and founder of Medicofarma, a Polish CMO, discusses the company’s recent upgrades to double production capacity and the move into R&D operations as well as the dynamics…
Andrzej Schonert, CEO of Synoptis Industrial, discusses the intricacies of the Polish market and the requirement to move into niche areas, mainly in Rx, to concentrate their pharmaceutical offering to…
See our Cookie Privacy Policy Here